The purpose of this statement is to update previous information and recommendations provided by the Committee for the use of Haemophilus influenzae type b conjugate vaccines1 in view of the licensure of a new product. Our initial recommendations concerned the use of PRP-D, a vaccine consisting of the capsular polysaccharide of Haemophilus influenzae type b conjugated to diphtheria toxoid, which was licensed for use in December 1987.

This content is only available via PDF.